Mar-23
IDC MarketScape: Worldwide Life Science Sales and Marketing Strategic Consulting Services 2023 Vendor Assessment
IDC MarketScape: Worldwide Life Science Sales and Marketing Strategic Consulting Services 2023 Vendor Assessment
Mar-23 DOC # US50407723 IDC DecisionScape
This IDC study provides an assessment of 12 vendors offering strategic consulting solutions for sales and marketing processes in the life science industry. Digital transformation is occurring at a rapid pace in life science companies, including in the sales and marketing space. Internal and external sources of data are being collected in the cloud, and this information is being leveraged by sales and marketing groups to improve speed, efficiency, and effectiveness in reaching customers, including both healthcare providers and patients. Tools such as artificial intelligence (AI), advanced analytics, and orchestration of multiple tasks and roles utilizing data from multiple sources are accelerating change in 2023 and beyond and helping expand the scope of business processes suitable for outsourcing to qualified vendors.
Mike Townsend, research director for Life Science Commercial Strategies at IDC Health Insights, says, "Life science companies are embracing digital transformation efforts within sales and marketing, which can connect stakeholders such as sales representatives, marketing and medical affairs executives, doctors, patients, and payers using a wide variety of digital technologies, including AI, cloud computing, mobile technology, and social media and analytics, and leveraging a host of internal and external data sources. Highly experienced strategic consulting vendors are offering increasingly sophisticated business models for processes leveraging these technologies while allowing these companies to focus on their core competencies. Life science companies will continue to see improved outcomes, growth, and productivity as they free their organizations to focus on core innovation and business cases, using these offerings to improve outcomes for doctors and patients alike."
Dec-22
Medidata NEXT 2022: Solving the Impossible
Medidata NEXT 2022: Solving the Impossible
Dec-22 DOC # US49893022 Insight
This IDC Perspective reviews the industry analyst event recently hosted by Medidata (a Dassault Systemes [DS] company) from November 15 to 16, 2022, in New York. It was addressed by Life Sciences and Healthcare Sector Board Chairman, DS, Tarek Sherif; co-CEOs of Medidata (Rama Kondru and Sastry Chilukuri); and the CEO of Patient Cloud (Anthony Costello), as well as Medidata's leadership, partners, and customers who outlined the new offerings and the strategic road map for Medidata in life sciences.
"As technology adoption continues to scale rapidly in the life sciences industry, the industry and technology providers continue to innovate; pharmas and biotechs are looking for solutions that will drive quality and compliance, accelerate time to market, and weave in both a site-centric and a patient-centric focus. Technology solutions that power decentralized clinical trials, that drive diversity and equity, that improve access, that integrate a risk-based quality management strategy, and that drive interoperability will serve as differentiators and define the pace of innovation for the life sciences industry," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.
"Consolidated clinical trial results, augmented by real-world data and patient and provider insights, can help construct rich patient journey experiences that help life sciences companies and healthcare providers find patients who can benefit from innovative therapies and result in improved health outcomes and better knowledge sharing between researchers, medical affairs experts, providers, and patients," says Michael Townsend, research director, Life Sciences Commercial Strategies at IDC Health Insights.
Dec-22
Life Science Revenue Management in the Cloud, 2022
Life Science Revenue Management in the Cloud, 2022
Dec-22 DOC # US49929722 Presentation
This IDC Survey Spotlight analyzes trends and deployment plans based on results from IDC's Industry CloudPath Survey (April 2022) and IDC's Life Sciences DX Survey (March 2022). Life science companies are increasingly deploying their revenue management solutions in the cloud.
Dec-22
Deployment of AI in Life Science Commercial Use Cases, 2022
Deployment of AI in Life Science Commercial Use Cases, 2022
Dec-22 DOC # US49938422 Presentation
This IDC Survey Spotlight analyzes deployment of AI in selected life science commercial applications and use cases, based on responses in IDC's Industry AI Path Survey, September 2022.
Nov-22
State of the Market: Health and Life Sciences — Inflation Impact on IT Spending and the Cloud
State of the Market: Health and Life Sciences — Inflation Impact on IT Spending and the Cloud
Nov-22 DOC # US49812322 Presentation
This IDC Tech Buyer Presentation delves deeper into the impact of inflation on healthcare and life science organizations and includes a discussion of the looming recession. Our analysis also offers IDC's outlook on IT spending and global economics sentiments gleaned from IDC's Future of Enterprise Resiliency and Spending (FERS) Survey.
Analysts across IDC Insights evaluated the impact of eight inflation triggers on their respective industries: supply chain constraints, localized labor shortages, raw materials and component costs, salary increases, tariffs and fiscal policy, energy costs, interest rates, and business margins.
"Inflation is leading health and life sciences organizations to prioritize investments in technologies such as cloud, AI/ML, automation, and advanced analytics, which reduce costs; improve efficiency, productivity, and decision making; and address labor shortages and supply chain constraints." — Lynne A. Dunbrack, group vice president, IDC Health Insights
Oct-22
IDC FutureScape: Worldwide Healthcare Industry 2023 Predictions
IDC FutureScape: Worldwide Healthcare Industry 2023 Predictions
Oct-22 DOC # US48587222 IDC DecisionScape
This IDC study provides executives across the globe with actionable insights and analysis for future healthcare industry scenarios.
"The 2023 worldwide healthcare industry predictions focus on the major storms of disruption for the foreseeable future, big tech flips, and how healthcare organizations can prepare for and respond to them," says Mutaz Shegewi, research director, IDC Health Insights. "Technological strategies and capabilities will determine how healthcare organizations navigate the aftereffects of the global COVID-19 pandemic combined with the impact of everything from inflationary pressures to supply chain constraints, labor and skills shortages, the Russia-Ukraine War, and other geopolitical threats. Healthcare organizations also face escalating cybersecurity risks, shifting care models, and an ongoing need to strive for service excellence while addressing broader, systemic challenges. Opportunities present alongside each challenge; however, healthcare organizations must act quickly because the next five years will prove that the storms are not temporary but lasting and interwoven."
Oct-22
IDC FutureScape: Worldwide Life Sciences 2023 Predictions
IDC FutureScape: Worldwide Life Sciences 2023 Predictions
Oct-22 DOC # US48585622 IDC DecisionScape
This IDC study discusses the top 10 predictions for the life science industry for 2023.
"The 2023 worldwide life science industry predictions focus on the explosion of an ecosystem of digital-native innovators. They are powering a precision medicine strategy, fueling the increased confluence between healthcare and life sciences, scaling sustainability by design initiatives driven by the increasing importance of ESG, and focusing on persistent immersive experiences, led by an extreme obsession with 'data centricity' and 'patient centricity,'" says Dr. Nimita Limaye, research VP, Life Sciences R&D Strategy and Technology at IDC Health Insights.
Oct-22
Life Science Digital Transformation Business Drivers, 2022
Life Science Digital Transformation Business Drivers, 2022
Oct-22 DOC # US49740922 Presentation
This IDC Survey Spotlight examines life science digital transformation business drivers for 2022.
Life science companies are investing in digital transformation to improve processes and engagement throughout their business. In IDC's March 2022 Life Sciences DX Survey, respondents rated the importance of business drivers for their digital transformation initiatives in various industry processes and their spending plans for 2022.
Sep-22
Health Data Platforms in Life Science Digital Transformation, 2022
Health Data Platforms in Life Science Digital Transformation, 2022
Sep-22 DOC # US49708322 Presentation
This IDC Survey Spotlight features data from IDC's March 2022 Life Sciences DX Survey, is which respondents rated the importance of health data platforms to their organizations from digital transformation initiatives in various industry processes and their spending plans for 2022. Life science companies are embracing health data platforms in their digital transformation initiatives.
Jul-22
IDC's Worldwide Digital Transformation Use Case Taxonomy, 2022: Life Sciences
IDC's Worldwide Digital Transformation Use Case Taxonomy, 2022: Life Sciences
Jul-22 DOC # US49278522 Study
This IDC study discusses how digital transformation accurately characterizes the life science industry's ongoing efforts to transform itself as it seeks to find new paths to innovation, optimize operational efficiency and effectiveness, and regain long-term sustainability. As in other industries, the digital transformation journey begins with a common definition of the mission, strategic priorities, and programs so that individual projects or use cases can better align with a life science company's overall goals and objectives.
"Digital transformation continues to transform patient and HCP engagement and fuel innovation in the life science industry. With the increasing adoption of newer technologies such as federated learning platforms, prescription digital therapeutics, and the metaverse, including AR, VR, and MR, it is essential to have a clear understanding of the digital taxonomy for life sciences and to be cognizant of the use cases where these disruptive technologies are being applied," says Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology, IDC Health Insights.
"Digital transformation in the life science industry is moving forward rapidly. 3rd Platform technologies such as cloud, mobile, big data and analytics, and social data are already woven into the life science commercial arena. Emerging technologies like AI and RPA are accelerating productivity for commercial teams by maximizing message impact and relevance while reducing duplicate or confusing interactions with HCPs. In life science supply chains, IoT networks and platforms are enabling tracking and monitoring of sensitive and rare biologic drugs, allowing rapid deployment to patients in critical need around the globe. From the manufacturing floor to doctors' offices, digital technology is improving quality, efficiency, and patient experience," says Michael Townsend, research director, Commercial Life Sciences, IDC Health Insights.
Jun-22
IDC Health Insights' Knowledge-Based Medicine: Digital Transformation in Life Sciences, 2022
IDC Health Insights' Knowledge-Based Medicine: Digital Transformation in Life Sciences, 2022
Jun-22 DOC # US49300622 Presentation
This IDC Tech Buyer Presentation identifies the digital transformation (DX) use cases associated with life sciences strategies and provides guidance on how to prioritize them to develop a DX road map.
Jun-22
Life Sciences Commercial Digital Transformation Use Cases — Build or Buy?
Life Sciences Commercial Digital Transformation Use Cases — Build or Buy?
Jun-22 DOC # US49279622 Presentation
This IDC Survey Spotlight uses data from IDC's Life Sciences DX Survey to illustrate trends and strategies relating to build versus buy decisions for 11 commercial use cases. IDC Health Insights conducted this survey of over 200 IT and line-of-business (LOB) executives at life science companies to understand the current approaches to digital transformation (DX). Vendors may include either software or service providers.
Jun-22
Benefits of Digital Transformation in Life Science Commercial Processes, 2022
Benefits of Digital Transformation in Life Science Commercial Processes, 2022
Jun-22 DOC # US49237422 Presentation
This IDC Survey Spotlight highlights the benefits of digital transformation in life science commercial processes. Life science companies are benefiting from digital transformation initiatives in their commercial processes. In IDC's Life Sciences DX Survey, March 2022, respondents rated the benefits to their organizations from digital transformation initiatives in various industry processes.
Apr-22
Infosys and Top Pharma Bring Digital Transformation to Drug Manufacturing Data
Infosys and Top Pharma Bring Digital Transformation to Drug Manufacturing Data
Apr-22 DOC # US47726621 Insight
This IDC Perspective highlights how Infosys and a top 20 global pharmaceutical company bring digital transformation to drug manufacturing data. Analytics and data operations in biopharmaceutical manufacturing hold great potential for speeding lifesaving and life-improving drugs to manufacture while improving quality and efficiency. As pressure increases on drug companies to lower prices and costs, digital transformation in manufacturing data analytics offers a great opportunity to accomplish both.
"Life science companies are beginning to realize the fruits of their investments in digital transformation on the manufacturing floor by improving access to real-time data and providing platforms and analytics tools that generate valuable insights, allowing actions that improve quality and save time," according to Michael Townsend, research director for Life Sciences Commercial Strategies at IDC Health Insights
Mar-22
Digital Transformation Drivers in Life Sciences
Digital Transformation Drivers in Life Sciences
Mar-22 DOC # US48986220 Presentation
This IDC Survey Spotlight examines which technologies are driving digital transformation in life science companies today and in the next four years, according to respondents to IDC's July 2020 Industry IT and Communications Survey.
Mar-22
IDC Perspective: Real-World Evidence and Drug Pricing in 2022
IDC Perspective: Real-World Evidence and Drug Pricing in 2022
Mar-22 DOC # US47235421 Insight
This IDC Perspective discusses real-world evidence and drug pricing in 2022. Prescription drug pricing, especially in the United States, has become a widely discussed issue for patients, private and government healthcare payers, life science companies, and society at large. "As life science companies, private and public healthcare payers, and healthcare providers learn to use RWE to discover the true value of prescription drug therapies, drug prices will increasingly be based on actual outcomes for patients. In the long run, this will benefit all stakeholders in the healthcare ecosystem in the United States and around the world," says Michael Townsend, research director for Life Science Commercial Strategies at IDC Health Insights.
"While one transitions from a commoditized pricing model to a value-based, pay-for-performance model that typically applies to very expensive drugs, one needs to remember that this is still creating value for only a limited few, as this would be cost prohibitive for the rest. True value will be realized when there exist pricing models that enable access to all. Value can be perceived as quantitative improvement in clinical outcomes for a patient, as quality-of-life improvements for both patients and their caregivers, and as the reduction in health burden or the eradication of disease, at a population health level. Real-world data is a crucial asset to assess this value, and pharma companies need to engage in early dialog with payers to determine what data they need to provide to support pricing decisions," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology, IDC.
Mar-22
IDC MarketScape: Worldwide Life Science Sales and Marketing IT Outsourcing Services 2022 Vendor Assessment
IDC MarketScape: Worldwide Life Science Sales and Marketing IT Outsourcing Services 2022 Vendor Assessment
Mar-22 DOC # US41808017 IDC DecisionScape
This IDC study provides an assessment of 11 vendors offering IT outsourcing solutions for sales and marketing processes in the life science industry. Digital transformation is occurring at a rapid pace in life science companies, including in the sales and marketing space. Data from internal and external sources is being collected in the cloud, and this information is being leveraged by sales and marketing groups to improve speed, efficiency, and effectiveness in reaching customers, including both healthcare providers and patients. Tools such as AI, advanced analytics, and orchestration of multiple tasks and roles utilizing data from multiple sources are accelerating change in 2022 and beyond and helping expand the scope of business processes suitable for outsourcing to qualified vendors.
Mike Townsend, research director for Life Science Commercial Strategies at IDC Health Insights, says, "Life science companies are embracing digital transformation efforts within sales and marketing, which can connect stakeholders such as sales representatives, marketing and medical affairs executives, doctors, patients, and payers using a wide variety of digital technologies, including AI, cloud computing, mobile technology, and social media and analytics, and leveraging a host of internal and external data sources. Highly experienced vendors are offering increasingly sophisticated ITO models for processes leveraging these technologies while allowing these companies to focus on their core competencies. Life science companies will continue to see improved outcomes, growth, and productivity as they free their organizations to focus on core innovation and business cases, using these offerings to improve outcomes for doctors and patients alike."